News for Carefree Group, Inc. (CRFU)

Published at

Jun 14, 2024 4:02 PM

by marketscreener.com

positive

positive

J&J: encouraging trial in relapsing multiple myeloma

Johnson & Johnson reports that long-term data from a Phase 1/2 study showed that after a median follow-up of 20-30 months, Talvey maintained sustained high response rates in patients with relapsed...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

May 16, 2024 1:36 PM

by marketscreener.com

positive

positive

Johnson & Johnson to acquire Proteologix for $850 million

Johnson & Johnson on Thursday said it would acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment. (Reporting by Sriparna Roy in Bengaluru;...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Apr 29, 2024 1:40 PM

by investing.com

mixed

mixed

Analysis-Central Europe's rate-setters have pause for thought By Reuters

Analysis-Central Europe's rate-setters have pause for thought

CRFU CNBZ CNBW CBSU MSCL.SN

Read more →
Published at

Apr 3, 2024 3:19 PM

by marketscreener.com

positive

positive

J&J: working for greater health equity in the USA -April 03, 2024 at 09:19 am EDT

Johnson & Johnson announces that it is working with more than 100 community health organizations to improve health equity in the United States. Indeed, J&J reports that studies have shown that people...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Mar 27, 2024 8:32 PM

by marketscreener.com

positive

positive

J&J gets new opportunity to contest evidence linking talc to cancer

Johnson & Johnson will get a new chance to contest the scientific evidence linking talc products to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting a federal court case...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Mar 27, 2024 4:41 PM

by marketscreener.com

positive

positive

J&J: Fast Track designation for nipocalimab -March 27, 2024 at 11:41 am EDT

Johnson & Johnson announced today that the US Food and Drug Administration has granted Fast Track Designation to nipocalimab to reduce the risk of FNAIT in women during pregnancy. The laboratory...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Mar 26, 2024 7:23 PM

by marketscreener.com

positive

positive

Johnson & Johnson considers deal for Shockwave Medical, WSJ reports

Johnson & Johnson is considering a deal for Shockwave Medical, the Wall Street Journal reported on Tuesday. ...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Mar 1, 2024 8:44 PM

by marketscreener.com

positive

positive

FDA approves JNJ's combination therapy for patients with a type of lung cancer

The FDA said on Friday it has approved Johnson & Johnson's therapy in combination with other chemotherapies for the first-line treatment of a type of lung cancer. (Reporting by Sriparna Roy in...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Jan 23, 2024 4:04 PM

by marketscreener.com

positive

positive

Trending : Johnson & Johnson 4Q Tops Views; Talc Settlement Near -January 23, 2024 at 10:04 am EST

09:48 ET -- Johnson & Johnson is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The healthcare giant posted...

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Dec 13, 2023 3:28 PM

by marketscreener.com

positive

positive

J&J: promising results in multiple myeloma -December 13, 2023 at 09:28 am EST

Johnson & Johnson has announced new results from a Phase III study of Carvykti in adults with relapsed lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy ....

JNJ DJNJ3.BA DJNJ2.BA CRFU

Read more →
Published at

Sep 19, 2022 8:30 PM

by marketscreener.com

neutral

neutral

Amerityre : Annual Report for Fiscal Year Ending June 30, 2022 (Form 10-K)

amerityre20220630_10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ... | September 19, 2022

CRFU AMTY

Read more →